-
2024-518553-41-00
5
2024-11-08
colon cancer and rectal with liver metastasis
-
2024-513540-29-00
5
2024-11-07
Breast Cancer
-
2023-505617-24-00
4
2024-11-05
Recurrent Ovarian Cancer with High Folate Receptor-Alpha Expression
-
2023-505423-31-00
5
2024-08-08
advanced or metastatic gastric adenocarcinoma, gastroesophageal juncti
-
2023-506054-20-00
5
2024-06-05
Adenocarcinoma of the biliary tract (intrahepatic or extrahepatic chol
-
2022-502043-35-01
5
2024-04-24
Advanced Biliary Tract Cancers
-
2023-504816-14-00
5
2024-03-08
Endometrial cancer
-
2023-505972-32-00
5
2024-02-26
locally advanced anal squamous cell carcinoma
-
2022-502975-45-00
5
2023-12-12
Metastatic leiomyosarcoma
-
2023-503265-27-00
5
2023-11-23
Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Co
-
2023-508945-41-00
4
2023-10-11
Hepatocellular Carcinoma
-
2022-502012-37-00
5
2023-10-06
Advanced Hepatocellular Carcinoma
-
2023-503652-27-00
5
2023-10-06
Melanoma
-
2022-502593-17-00
5
2023-09-19
Locally advanced or metastatic hormone receptor (HR)-positive, human e
-
2022-502322-41-00
5
2023-09-12
Metastatic breast cancer
-
2022-501024-20-00
5
2023-07-25
ER+/HER2- Early Breast Cancer
-
2022-501570-18-00
1
2023-07-18
Recurrent or metastatic Head and NeckSquamous Cell Carcinoma of the or
-
2022-500637-80-00
5
2023-03-28
gastrointestinal stromal tumor
-
2022-501217-31-00
10
2023-03-09
Hepatocellular carcinoma
-
2023-505552-22-00
5
2023-02-24
Stage I-III Triple-negative Breast Cancer with residual invasive disea
-
2023-504027-78-00
4
2023-01-13
Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
-
2023-510061-10-00
3
2023-01-09
Clear cell renal cell carcinoma (ccRCC, first-, second- and third-line
-
2024-514644-93-00
5
2022-12-09
Metastatic renal cell carcinoma (mRCC) with a good or only one adverse
-
2024-513882-38-00
10
2022-10-12
Intermediate stage Hepatocellular carcinoma